Wolfram Syndrome Clinical Trials: Advancing Treatments from Medications to Gene-Editing

Overview

Dr. Fumi Urano from Washington University discussed Wolfram Syndrome clinical trials, focusing on advancing treatments from oral medications to gene editing. Wolfram Syndrome, a rare genetic disorder with a median age of onset at 6 for diabetes and 11 for optic nerve atrophy, affects 1 in 250,000 to 700,000 people. Dr. Urano highlighted the severity categorization system (1-6) based on mutation types and shared a case study of a patient with mild manifestations due to a common Ashkenazi Jewish variant. The study on AMX 35, a drug to mitigate endoplasmic reticulum stress, showed improved insulin production and glycemic control in a 48-week clinical trial. Future steps include gene editing therapy and regenerative therapy.
Read more

/by

Wolfram syndrome: from physiopathology to therapy – Virtual Global Research and Trial Updates

Overview

The meeting discussed Wolfram syndrome, focusing on its physiopathology and potential therapies. Benjamin Delprat presented his research from Inserm, Montpellier, highlighting the role of the WFS1 protein and its interaction with NCS1 and IP3R in cellular calcium transfer. He proposed gene therapy using self-complementary AAV9 vectors to overexpress NCS1 and pharmacological therapy targeting the sigma-1 receptor. Preclinical studies in zebrafish showed that NCS1 overexpression corrected mitochondrial impairment, while sigma-1 receptor agonists improved hyperlocomotion. Future work includes validating these findings in mouse models and identifying new sigma-1 receptor modulators.
Read more

/by

Preliminary results on the Tirzepatide monotherapy in Wolfram syndrome trial – Virtual Global Research and Trial Updates

Overview

Dr. Giulio Frontino and Amelia Caretto presented preliminary results from a trial on Tirzepatide monotherapy for Wolfram syndrome. The trial, involving 17 patients (including children and adults), showed stabilization of C-peptide levels in half of the patients, with a median increase of 15% over two years. Tirzepatide improved beta-cell function and reduced inflammation markers. However, retinal nerve fiber layer thickness decreased in some patients, possibly due to pubertal hormonal changes. The trial also noted stable BMI and improved HbA1c levels. Side effects were mild and manageable, with no severe adverse events reported.
Read more

/by

A Hidden Diagnosis: Neurogenic Bladder Leading to Acute Kidney Failure in Wolfram Syndrome

Publication: cureus.com | Publication Date: 6 May 2025

Authors: Nadia Echcharii, Nabila Chekhlabi, Amal Haoudar, Nezha Dini

Abstract

Wolfram syndrome (WS) is a rare, autosomal recessive neurodegenerative disorder characterized by progressive multisystemic involvement, including diabetes mellitus, optic atrophy, diabetes insipidus, sensorineural hearing loss, and urological dysfunction. While diabetes mellitus is typically the first clinical sign, atypical presentations can delay the diagnosis.

Read more

/by

A Rare Case of Wolfram Syndrome in a 27-Year-Old Male From Nepal

Publication: cureus.com | Publication Date: 25 October 2025

Authors: Tej P. Shah, Richard Sidlow, Prem K. Sah

Abstract

Wolfram syndrome is a rare autosomal recessive disorder characterized by diabetes mellitus, optic atrophy, and progressive neurodegeneration, often summarized by the acronym DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness). We report a 27-year-old male with a history of diabetes mellitus, progressive visual loss leading to blindness, and bilateral sensorineural hearing loss. His family history was notable for diabetes-related mortalities and visual impairment in multiple members of the family. Clinical evaluation showed uncontrolled blood glucose level, optic atrophy, and high-frequency sensorineural hearing loss. A clinical diagnosis of Wolfram syndrome was made using the Euro-Wolfram, Alström, and Bardet-Biedl (WABB) criteria. Wolfram syndrome should be suspected in young patients with early-onset diabetes mellitus and visual or hearing impairment. This case report highlights the role of timely multidisciplinary management in preventing disease-related complications.

Read more

/by

Expanding the spectrum of white matter abnormalities in Wolfram syndrome: A retrospective review

Publication: frontiersin.org | Publication Date: 14 October 2025

Authors: Justin Simo, Heather M. Lugar, Elka Miller, Adi Wilf-Yarkoni, Yael Goldberg, Ayça Kocaağa, Shoichi Ito, Sirio Cocozza, Giulio Frontino, Cristina Baldoli, Aziz Benbachir, Catherine Ashton, Guy Rouleau, Tamara Hershey, Yann Nadjar, Roberta La Piana

Background and Objectives

Wolfram syndrome (WFS) is a genetic disorder mainly caused by pathogenic variants in the WFS1 gene. It is characterized clinically by optic atrophy (OA), diabetes mellitus (DM), sensorineural hearing loss (SNHL), diabetes insipidus (DI), and variable neurological/psychiatric symptoms. WFS typically manifests before age 20 and progresses into adulthood. Classical neuroradiological features include cerebellar and/or brainstem atrophy as well as white matter abnormalities ranging from small, ovoid lesions to diffuse, symmetrical changes along the visual pathway. Following the identification of multifocal, progressive white matter abnormalities that prompted the consideration of multiple sclerosis (MS) in two molecularly confirmed WFS subjects, we sought to verify whether MS-like lesions constitute a novel WFS-associated MRI pattern.
Read more

/by

Wolfram Syndrome Global Awareness Day 2025

Wolfram Syndrome Awareness Day is held on October 1st each year. This day was chosen because it is the anniversary of the publication of a 1998 paper on the discovery of the WSf1 gene associated with the syndrome. The day is dedicated to raising awareness of this rare genetic disorder, which affects the body’s metabolism, nervous system, and senses, and to encouraging support for research and treatments.

/by

FDA Patient Listening Session

On May 21, 2025, The Snow Foundation convened a group of patients (3) and caregivers (4) from across the Wolfram syndrome (WS) community for a virtual patient listening session with over 40 representatives from the Food and Drug Administration (FDA). The small, informal virtual meeting was designed to allow community members to share their lived experiences, perspectives, and unmet needs with FDA.

Read more

/by

Non-syndromic WFS1 mutations are not a rare cause of diabetes in Pakistan

Publication: onlinelibrary.wiley.com | Publication Date: 29 April 2025

Authors: Ibrar Rafique, Asif Mir, Natalija Popovic, Alix Vanpoperinghe, Muhammad Arif Nadeem Saqib, Asher Fawwad, Abdul Basit, Muhammad Naeem, Constantin Polychronakos, Angeliki Makri

Abstract

We examined 68 Pakistani patients with young onset diabetes and found a surprisingly high rate (4/68) of non-syndromic WFS1 diabetes, a recently described recessive condition. This frequency far exceeds the prevalence of the fully expressed syndrome, probing the effect of high consanguinity on the risk of non-syndromic WFS1 diabetes.
Read more

/by
, ,

TREATWOLFRAM international clinical trial of sodium valproate in Wolfram syndrome: interim results

First results from the TREATWOLFRAM trial, sponsored by the University of Birmingham, find sodium valproate treatment does not slow vision loss in Wolfram syndrome.

Read more

/by